Severe weather cited for discontinued manufacturing

Article

PixelOptics will discontinue the atLast! Line of enhanced multifocal lenses, due to winter flood damage at the company?s primary manufacturing site in Thailand, the company announced.

Roanoke, VA-PixelOptics will discontinue the atLast! Line of enhanced multifocal lenses, due to winter flood damage at the company’s primary manufacturing site in Thailand, the company announced. The line was launched worldwide in October 2008.

“It is with deep regret that we have made the decision to discontinue production on our family of atLast! products,” said Brett Craig, PixelOptics president and CEO. “Despite significant efforts to resolve supply issues following floods at our Thailand factory, it has become apparent that production cannot be restored in a timely manner to meet current demand. This decision was not taken lightly and we remain committed to supporting our customers through this period of transition.”

The company’s emPower! Line, manufactured in Japan, is not affected. The company said its U.S. rollout for emPower! is expected to continue and would be followed by a series of European launches throughout the year.

Although the company said the loss of its atLast line is unfortunate, it provides the company the ability to focus its full effort on emPower!

For more articles in this issue of InDispensable, click here.

Recent Videos
Optometrists reflect on their residency experiences and provide advice to current residents.
EnVision Summit Co-chairs Sherrol Reynolds, OD, FAAO; Katie Rachon, OD, FAAO, Dipl ABO; Jessica Steen, OD, FAAO, Dipl ABO; and Cecelia Koetting, OD, FAAO, Dipl ABO; express excitement for the upcoming conference and why optometrists should attend.
Bonnie An Henderson, MD, the cofounder and program director of EnVision Summit
What was the biggest innovation in eye care in 2024?
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
© 2024 MJH Life Sciences

All rights reserved.